BlossomHill Therapeutics, (BLSM) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $40.00 from $36.00 | Sep 21, 2026 |
| Guggenheim | Maintained | Buy | $40.00 from $30.00 | Sep 21, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $28.00 | Sep 1, 2026 |
| Guggenheim | Initiated Coverage | Buy | $30.00 | Sep 1, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $35.00 | Sep 1, 2026 |
| LifeSci Capital | Initiated Coverage | Outperform | $32.00 | Sep 1, 2026 |
| Leerink Partners | Initiated Coverage | Outperform | $36.00 | Sep 1, 2026 |
Frequently asked questions
What is the price target for BLSM stock?
The average 12-month analyst price target for BlossomHill Therapeutics, (BLSM) is $35.00, with a high estimate of $40.00 and a low of $28.00, across 5 analysts.
Is BLSM a buy, sell, or hold?
Analysts covering BlossomHill Therapeutics, currently average a Buy rating: 5 buy, 0 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BLSM?
The average price target of $35.00 implies 129.36% upside from the last price of $15.26.
What is the latest analyst rating on BLSM?
On Sep 21, 2026, Leerink Partners maintained BlossomHill Therapeutics, at Outperform with a price target of $40.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.